BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32966238)

  • 1. Bioinformatics analysis of the clinical value and potential mechanisms of AHNAK2 in papillary thyroid carcinoma.
    Xie Z; Lun Y; Li X; He Y; Wu S; Wang S; Sun J; He Y; Zhang J
    Aging (Albany NY); 2020 Sep; 12(18):18163-18180. PubMed ID: 32966238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
    Front Endocrinol (Lausanne); 2021; 12():646793. PubMed ID: 34122331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
    BMC Cancer; 2020 Nov; 20(1):1143. PubMed ID: 33238942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
    Zheng L; Li S; Zheng X; Guo R; Qu W
    Int Immunopharmacol; 2021 Jan; 90():107185. PubMed ID: 33218938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
    Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
    Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
    Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
    BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
    Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
    Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
    Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma.
    Xia F; Wang W; Jiang B; Chen Y; Li X
    Cancer Manag Res; 2019; 11():1249-1262. PubMed ID: 30799952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of KIF-12 Functioning as a Tumour Suppressor in Papillary Thyroid Carcinoma.
    Gao L; Liu R; Xia Y; Pan A; Shi X; Ma L; Ji J; Hu Y; Li X; An Y; Luo N; Liang Z; Zhou L; Jiang Y
    J Cancer; 2024; 15(8):2206-2213. PubMed ID: 38495495
    [No Abstract]   [Full Text] [Related]  

  • 11. F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer.
    Luo JH; Zhang XX; Sun WH
    Aging (Albany NY); 2022 Apr; 14(8):3687-3704. PubMed ID: 35483340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma.
    Zhang G; Li B; Lin Y
    Front Oncol; 2021; 11():614955. PubMed ID: 35174063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors.
    Gao T; Zhao L; Zhang F; Cao C; Fan S; Shi X
    World J Surg Oncol; 2022 Jun; 20(1):207. PubMed ID: 35710427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer.
    Tan J; Liu L; Zuo Z; Song B; Cai T; Ding D; Lu Y; Ye X
    Oncol Rep; 2020 Oct; 44(4):1489-1501. PubMed ID: 32945494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.
    Xia Y; Jiang X; Huang Y; Liu Q; Huang Y; Zhang B; Mei Z; Xu D; Shi Y; Tu W
    Front Endocrinol (Lausanne); 2022; 13():895428. PubMed ID: 35757399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential diagnostic of lymph node metastasis and prognostic values of TM4SFs in papillary thyroid carcinoma patients.
    Wang K; Li H; Zhao J; Yao J; Lu Y; Dong J; Bai J; Liao L
    Front Cell Dev Biol; 2022; 10():1001954. PubMed ID: 36568979
    [No Abstract]   [Full Text] [Related]  

  • 17. HIF1A overexpression predicts the high lymph node metastasis risk and indicates a poor prognosis in papillary thyroid cancer.
    Zhao YX; Yang Z; Ma LB; Wang F; Wang Y; Xiang C
    Heliyon; 2023 Mar; 9(3):e14714. PubMed ID: 36994412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADORA1 is a diagnostic-related biomarker and correlated with immune infiltrates in papillary thyroid carcinoma.
    Lin X; Wang ZY; Xue G; Qin XJ; Wu JF; Zhang G
    J Cancer; 2021; 12(13):3997-4010. PubMed ID: 34093805
    [No Abstract]   [Full Text] [Related]  

  • 19. Insight of novel biomarkers for papillary thyroid carcinoma through multiomics.
    Liu W; Zhu J; Wu Z; Yin Y; Wu Q; Wu Y; Zheng J; Wang C; Chen H; Qazi TJ; Wu J; Zhang Y; Liu H; Yang J; Lu D; Zhang X; Ai Z
    Front Oncol; 2023; 13():1269751. PubMed ID: 37795451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
    Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
    Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.